WAWerner Apt

Werner Apt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Werner Apt has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Inés Zulantay

    Laboratory of Basic-Clinical Parasitology, Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile

    11 shared publications
  • Arturo Arribada

    Service of Cardiology, Clínica INDISA, Santiago, Chile

    4 shared publications
  • Miguel Saavedra

    Laboratorio de Parasitología Básico-Clínico, Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Independencia 1027, Santiago, Chile

    4 shared publications
  • Jorge Rodríguez

    Escuela de Salud Publica, Facultad de Medicina, Universidad de Chile, Santiago, Chile

    3 shared publications
  • Catalina Muñoz-San Martín

    Laboratorio de Parasitología Básico-Clínico, Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile

    2 shared publications
  • Catalina Muñoz-San Martín

    Escuela de Medicina Veterinaria, Facultad de Ciencias Médicas, Universidad Bernardo O’Higgins, Santiago 8370993, Chile

    2 shared publications

Latest Publications

  • Open Access

    Discrete Typing Units of Trypanosoma cruzi Identified by Real-Time PCR in Peripheral Blood and Dejections of Triatoma infestans Used in Xenodiagnosis Descriptive Study

    by Inés Zulantay, Gabriela Muñoz, Daniela Liempi, Tamara Rozas, María José Manneschi, Catalina Muñoz-San Martín, Carezza Botto-Mahan, Werner Apt, Gonzalo Cabrera

    Chagas disease (ChD) is a vector zoonosis native to the American continent caused by the protozoan parasite Trypanosoma cruzi; the biological vectors are multiple species of hematophagous insects of the family Triatominae. A relevant aspect in the host–parasite relationship is the identification of the various genotypes of T. cruzi called discrete typing units (DTU) that circulate in mammals and vectors. In Chile, it has been described that the DTUs TcI, TcII, TcV, and TcVI circulate in infected humans, vectors, and wild animals. Identifying DTUs has acquired clinical importance, since it has been suggested that different genotypes could cause distinct pathologies, circulate in different geographical areas, and present different sensitivities to trypanocidal drugs. In this study, circulating T. cruzi DTUs in peripheral blood and Triatoma infestans dejections used in xenodiagnosis (XD) were amplified by qPCR in 14 Chilean patients with chronic ChD from highly endemic areas. More positive samples were detected by XD compared to peripheral blood samples, and 64.28% of the cases were simple infections and 35.72% mixed, with a statistically significant difference in the frequency of TcV DTU. This study would suggest that T. infestans from Chile is more competent to amplify one DTU over others, probably due to a process of co-evolution.


  • Open Access

    Clinical, electrocardiographic and echocardiographic evolution of chronic Chagas disease treated with nifurtimox on prolonged follow‐up in Chile: observational study

    by Werner Apt, Marcelo Llancaqueo, Inés Zulantay, Mauricio Canals, Sergio Kara, Arturo Arribada, Gabriela Muñoz, Gabriela Martínez


  • Discrete typing units of Trypanosoma cruzi detected by real-time PCR in Chilean patients with chronic Chagas cardiomyopathy

    by Catalina Muñoz-San Martín, Inés Zulantay, Miguel Saavedra, Cristián Fuentealba, Gabriela Muñoz, Werner Apt


  • Chronic Chagas cardiopathy in Chile. Importance of Trypanosoma cruzi burden and clinical evaluation

    by Werner Apt, Arturo Arribada, Inés Zulantay, Miguel Saavedra, Catalina Muñoz, Bruno Toro, Bastián Vega, Jorge Rodríguez


  • Open Access

    Quantification by real-time PCR of Trypanosoma cruzi DNA in samples of Triatoma infestans used in xenodiagnosis of chronic Chagas disease patients

    by Miguel Saavedra, Inés Zulantay, Werner Apt, Juan Castillo, Eduardo Araya, Gabriela Martínez, Jorge Rodríguez

    Trypanosoma cruzi multiplies and differentiates in the digestive tract of triatomine insects. Xenodiagnosis (XD) is a parasitological tool in which the insect vectors acts as a biological culture medium to amplify and detect T. cruzi infection in mammals. The sensitivity of XD has been overcome by the application of PCR in fecal samples (FS) of XD (PCR-XD). In this study, T. cruzi amplified in Triatoma infestans fed by XD on individuals with chronic Chagas disease (CChD) is quantified by real-time PCR (qPCR-XD). Under informed consent, 100 individuals were evaluated. In 21 of them XD, PCR-XD and qPCR-XD were positive. For the contrary, 79 were negative XD. In 58 (73.4 %) and 66 cases (83.5 %) of them, PCR-XD (Fisher’s exact test P = 0.005) and qPCR-XD (Fisher’s exact test: P = 0.037) respectively, were positive. In cases with positive XD, qPCR-XD allowed to establish that in 9/21 cases (42.9 %) the parasite burden fluctuated between 100 and 1,000 par. eq./ml. Otherwise, in 32/79 (40.5 %) cases with negative XD, a parasite burden between 1 and 10 par. eq./ml was determined. All samples showed amplification of exogenous internal control (X12, Ct average: 31.8), so problems in the DNA extraction (excess or loss of genetic material), unspecific amplification and/or inhibition in qPCR-XD reactions were ruled out. Additionally, in all the patients qPCR in blood (qPCR-B) was performed. In the cases with positive XD, the concordance between the positivity of qPCR-XD and qPCR-B was 100 %, nevertheless, the parasite burden in blood was lower and different than XD (Chi-square test: χ 2 = 91.82, df = 5, P = 0.0001). In the cases with negative XD the ranges of qPCR-XD and qPCR-B were similar (Chi-square test: χ 2 = 6.71, df = 5, P = 0.1520). This study allowed the detection and quantification of T. cruzi by qPCR-XD in FS of Tr. infestans fed on patients with CChD. The highest parasite burden was observed in positive XD cases. qPCR-XD could be used in different studies related with the complex T. cruzi-vector-host interactions.


  • Open Access

    Trypanosoma cruzi burden, genotypes, and clinical evaluation of Chilean patients with chronic Chagas cardiopathy

    by Werner Apt, Arturo Arribada, Inés Zulantay, Miguel Saavedra, Eduardo Araya, Aldo Solari, Sylvia Ortiz, Katherine Arriagada, Jorge Rodríguez

    There are currently no biomarkers to assess which patients with chronic indeterminate Chagas disease will develop heart disease and which will spend their entire life in this state. We hypothetize that the parasite burden and Trypanosoma cruzi genotypes are related to the presence of heart disease in patients with Chagas disease. This study is aimed to investigate the parasite burden and T. cruzi genotypes in chagasic cardiopaths versus chagasic individuals without cardiac involvement according to the New York Heart Association. Patients with chronic Chagas disease, 50 with and 50 without cardiopathy (controls), groups A and B, respectively, were submitted to anamnesis, physical examination, and electrocardiogram. Echo-Doppler was performed for group A; all important known causes of cardiopathy were discarded. Xenodiagnosis, conventional PCR, and quantitative PCR were performed on patients of both groups. T. cruzi genotyping was done for 25 patients of group A and 20 of group B. The 50 cardiopaths had 80 electrocardiographic alterations, most of them in grade II of the New York Heart Association classification; 49 were classified in grade I by Echo-Doppler, and only one patient was in grade III. The difference in average parasitemia in patients of groups A and B was not significant. The most frequent T. cruzi DTU found was TcV. The parasite burden and genotype of the groups with and without cardiopathy were similar. Imagen 1 Chronic chagas cardiopathy chest X-ray heart enlargement Figure 2 Chronic Chagas cardiopathy microaneurism of left ventricle. Cineangiography


  • Open Access

    Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up

    by Werner Apt, Arturo Arribada, Inés Zulantay, Jorge Rodríguez, Miguel Saavedra, Andrea Muñoz

    To evaluate cases of chronic Chagas' disease for the long-term effects of treatment with itraconazole on Trypanosoma cruzi infections and the regression or development of ECG abnormalities. In March 1992, we treated 46 patients with chronic Chagas' disease with 6 mg/kg/day of itraconazole for 120 days in a blind evaluation. The patients came from an area of Chile where the disease was endemic and were checked for ECG abnormalities and with xenodiagnosis (XD) or real-time XD-quantitative PCR (XD-qPCR) for Trypanosoma cruzi infection before treatment and once a year for 20 years. Twenty-one patients proved to be uninfected after 20 years and 15 of the patients had a normal ECG. Of the latter cases, 32.6% could be considered cured, although all of them had positive serology. Itraconazole prevents the development of ECG abnormalities, because after 20 years of treatment only 10.86% of patients developed ECG abnormalities (Z = 1.70, P = 0.046). XD-qPCR performed on 16 patients demonstrated 10 cases with <1.42 parasites/mL: eight with <1 parasite/mL, one with 1.42 parasites/mL and one with 1.01 parasites/mL. Five patients had more than 11.75 parasites/mL, all of them with a positive XD; these cases correspond to therapy failure, since re-infection was ruled out. In one case, XD-qPCR did not present amplification. Itraconazole is useful in the treatment of chronic Chagas' disease as it prevented the development of ECG abnormalities and cured 32.6% of patients.


  • Congenital infection by Trypanosoma cruzi in an endemic area of Chile: a multidisciplinary study

    by W. Apt, I. Zulantay, M. Arnello, D. Oddo, S. Gonzalez, J. Rodriguez, U. Kemmerling, C. Truyens, Y. Carlier

    This study investigated the prevalence of Chagas disease (ChD) in pregnant women in Choapa Province (IV Region, Chile) and the vertical transmission of Trypanosoma cruzi. ELISA and IFI IgG for ChD was performed for the pregnant women. PCR for T. cruzi was done for all chagasic mothers and their newborns. The congenital infection was confirmed by serial positive PCR and/or ELISA or IFI IgG after age of nine months. The placentas of mothers, with and without ChD, were submitted for histopathology and immunohistochemical study. From 4831 deliveries in 2005-2009 with a serological coverage of 88.6%, it was established that 147 cases (3.4%) had ChD. More than 80% of the pregnancies had a physiological evolution and 90% of the newborn were term. Congenital transmission was demonstrated in six children (4.7%) of the 127 newborn studied by serial PCR (at birth and/or between 3-18 months) and/or ELISA or IIF IgG after age nine months. Most of congenital cases were asymptomatic (67%). The histopathology shows edema, necrosis, fibrinoid deposit in the placentas of 28 of 29 chagasic mothers. In three cases the immnunochemistry demonstrated a decrease in actin expression in trophoblast cells. In one congenital case amastigote nests was observed. These results indicate that T. cruzi infection in pregnant women and vertical transmission in Chile are still prevalent. For this reason it is important to propose control measures in endemic areas of the country.


  • Open Access

    Real-Time PCR in faecal samples of Triatoma infestans obtained by xenodiagnosis: proposal for an exogenous internal control

    by Nicolás Bravo, Catalina Muñoz, Nicolás Nazal, Miguel Saavedra, Gabriela Martínez, Eduardo Araya, Werner Apt, Inés Zulantay

    Background: The polymerase chain reaction (PCR) has proved to be a sensitive technique to detect Trypanosoma cruzi in the chronic phase of Chagas disease, which is characterized by low and fluctuating parasitemia. Another technique proposed for parasitological diagnosis in this phase of infection combines a microscopic search for motile trypomastigote forms in faecal samples (FS) obtained by xenodiagnosis (XD) with conventional PCR (XD-PCR). In this study we evaluate the use of human blood DNA as an exogenous internal control (EIC) for real time PCR (qPCR) combined with XD (XD-qPCR) using chromosome 12 (X12) detection. Findings: None of the FS-XD evaluated by qPCR amplified for X12. Nevertheless, all the EIC-FS-XD mixtures amplified for X12. Conclusions: We determined that X12 is useful as an EIC for XD-qPCR because we showed that the FS-XD does not contain human DNA after 30 or more days of XD incubation. This information is relevant for research on T. cruzi by XD-qPCR since it allows ruling out inhibition and false negative results due to DNA loss during the process of extraction and purification.


    • 11 July 2011
      • Vol. 139  (2) , 247-57

    [Update on the treatment of Chagas' disease].

    by Werner Apt, Inés Zulantay

    Efficient drugs against Chagas' disease must have an effect on the amastigote forms or intracellular reproduction elements of Trypanosoma cruzi (T. cruzi). Trypomastigote and epimastigote forms derive from the former and their response to medications is less marked. The only drugs used in humans are nifurtimox (NF) and benznidazole (BNZ). Other useful medications are allopurinol and itraconazole. NF acts producing free radicals and BNZ inhibits the synthesis of macromolecules. There is consensus that Chagas' disease must be treated in all its periods, since T.cruzi DNA is detected by polymerase chain reaction in chronic cases, even when microscopy is negative. The pharmacological treatment modifies the natural evolution of the disease. It also helps to solve a public health problem, considering that there is a high number of subjects with Chagas' disease. Subjects with chronic chagasic cardiomyopathy with terminal heart failure are the only cases without indication for treatment. Due to the digestive and skin secondary effects of the drugs, treated patients must be controlled clinically and with complete blood counts and hepatic proiles before, during and after the therapy. Approximately 30% of patients will experience secondary effects. Children have a better tolerance to the drugs. Congenital or acquired acute, intermediate and chronic cases should be treated.